Part,  Chapter, Paragraph

 1   II,     5.  2.  7|              EHN: Bruxelles.~Daviglus ML, Stamler J, Pirzada A et
 2   II,     5.  2.  7|               292:1588-1592.~Daviglus ML, Liu K, Pirzada A, Yan LL,
 3   II,     5.  4.  8|        References~Armesto SG, Lapetra ML, Wei L, Kelley E and the
 4   II,     5.  5.  3|               Nicoletti A, Lo Bartolo ML, Lo Fermo S, et al (2001):
 5   II,     5.  5.  3|              May;14(4):574.~Sumelahti ML, Tienari PJ, Wikström J,
 6   II,     5.  5.  3| Neuroepidemiology 19:67-75.~Sumelahti ML, Tienari PJ, Wikström J,
 7   II,     5.  5.  3|          Scand 103:153-158.~Sumelahti ML, Tienari PJ, Hakama M, Wikström
 8   II,     5.  7.  1|            transplantation~2. GFR <60 ml/min/1.73 m2 , with or without
 9   II,     5.  7.  1|               Stage~Description~GFR*~(mL/min per 1.73 m2 )~ICD 9
10   II,     5.  7.  3|             CKD (defined as a GFR <75 ml/min per 1.74 m2 ) of 12.
11   II,     5.  7.  3|              7 cases /year pmarp (<30 ml/min per 1.74 m2 ) (Esbjorner
12   II,     5.  7.  3|             CKD (defined as a GFR <75 ml/min per 1.74 m2) of 74.7
13   II,     5.  7.  3|         cut-off for defining CKD (<30 ml/min per 1.74 m2 ), the corresponding
14   II,     5.  7.  7|               Lin J, Knight EL, Hogan ML, Singh AK (2003): A comparison
15   II,     5.  8.  4|         chronic bronchitis showed 252 mL lower forced expiratory
16   II,     5.  8.  5|              showed an increase of 47 ml FEV1, compared with a decrease
17   II,     5.  8.  5|        compared with a decrease of 49 ml FEV1 among continuing smokers (
18   II,     5. 11.  7|               142.~ ~Rea JN, Newhouse ML, Halil T (1976): Skin disease
19   II,     9.  1.  1|          Melvin CL, Kelsch C, Boulton ML (1999): Effects of smoking
20   II,     9.  3.  1|             cut off is 5 ng/dl (50 pg/ml)(0.17 nmol/L).~ ~In a joint
21   II,     9.  3.  1|      respectively: <180 pmol/L (52 pg/ml), between 180 and 250 pmol/
22   II,     9.  3.  1|             180 and 250 pmol/L (72 pg/ml) and > 250 pmol/L (52 pg/
23   II,     9.  3.  1|               and > 250 pmol/L (52 pg/ml).~ ~A complete diagnostic
24   II,     9.  3.  1|         London,~ ~Wizemann TM, Pardue ML (2001): Exploring the biological
25   II,     9.  3.  2|          Melvin CL, Kelsch C, Boulton ML (1999): Effects of smoking
26  III,    10.  2.  1|             104.~ ~Lobstein T, Frelut ML (2003): Prevalence of overweight
27  III,    10.  2.  1|         Romano MC, Lehingue Y, Frelut ML, Hercberg S (2002): Body
28  III,    10.  2.  1|                Rychlik E, Oltarzewski Ml (2003): Stan odzywienia
29  III,    10.  2.  5|             filtration speed (about 1 ml/minute each year after 40
30   IV,    11.  6.  5|           Policy 62: 243-273.~ ~Barer ML, Evans RG, Hertzman C, Lomas
31   IV,    11.  6.  5|             439-46.~ ~Evans RG, Barer ML (1995): "User fees for health